Clinical Trial

Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults

Name: Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults — clinical trial record (NCT07703956)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed with DSM-5 schizophrenia who are in an acute exacerbation phase.

Trial Details

NCT Number	NCT07703956
Lead Sponsor	Vigonvita Life Sciences
Conditions	Schizophrenia
Enrollment	500 participants
Start Date	2026-07-31
Primary Completion	2027-10-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-15